Abbott completes enrollment of Absorb™ randomized clinical trials in the United States, Japan and China
- Details
- Category: Abbott
Abbott (NYSE: ABT) today announced it has completed enrollment of three clinical trials to support approvals of the company's revolutionary Absorb™ Bioresorbable Vascular Scaffold (BVS) in the United States, Japan and China. Combined, the U.S., Japan and China account for more than 50 percent of the world's heart stent market.
Novartis and Malaria No More provide two million antimalarial treatments to children in Zambia
- Details
- Category: Novartis
Novartis announced today that two million treatments of its pediatric antimalarial are arriving in Zambia thanks to the ongoing efforts of the company in collaboration with Malaria No More's Power of One campaign. Zambia is the first beneficiary country of this campaign sponsored by Novartis.
Merck Serono enters into research agreement with Pfizer and Broad Institute
- Details
- Category: Merck Group
Merck Serono, the biopharmaceutical division of Merck, announced that its U.S. affiliate EMD Serono has signed a research agreement with Pfizer Inc. and the Broad Institute in Cambridge, Massachusetts, U.S. The collaboration is focused on the genomic profiling of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) patients. The research project will be jointly funded by Merck Serono and Pfizer.
Bayer HealthCare to significantly increase production capacity in China
- Details
- Category: Bayer
Bayer HealthCare will invest around EUR 100 million to significantly increase the production capacity of its plant in Beijing, China, in preparation for further demand of its products in the country. A respective agreement was signed in Germany on the occasion of the visit of the President of the People's Republic of China, Xi Jinping, by the CEO of Bayer AG, Dr Marijn Dekkers.
AstraZeneca and MRC enter strategic collaboration
- Details
- Category: AstraZeneca
AstraZeneca and the Medical Research Council (MRC) today announced that they have entered into a groundbreaking collaboration aimed at better understanding the mechanisms of human disease. The collaboration will see the creation of a joint research facility at AstraZeneca's new R&D centre in Cambridge in the UK.
Novo Nordisk launches 'Cities Changing Diabetes' to fight urban diabetes
- Details
- Category: Novo Nordisk
Novo Nordisk today announces the launch of 'Cities Changing Diabetes', an ambitious new partnership programme to fight the urban diabetes challenge. The 'Cities Changing Diabetes' programme will first be launched in Mexico City with other cities in North America, Europe and Asia soon to follow.
Where do you start when developing a new medicine?
- Details
- Category: GlaxoSmithKline
A pioneering public-private research initiative between GSK, the European Bioinformatics Institute (EMBL-EBI) and the Wellcome Trust Sanger Institute is to harness the power of 'big data' and genome sequencing to improve the success rate for discovering new medicines. The new Centre for Therapeutic Target Validation (CTTV) will aim to address a wide range of human diseases and will share its data openly in the interests of accelerating drug discovery.
More Pharma News ...
- Novartis announces US FDA approval of Xolair® for chronic idiopathic urticaria
- Bayer to invest more than 500 million Euros for the manufacturing of hemophilia A products currently in development
- Five Prime Therapeutics and Bristol-Myers Squibb sign collaboration agreement
- Sanofi and UCB partner for breakthrough innovation in immune-mediated diseases
- GSK increases stake in Indian Pharmaceuticals subsidiary to 75 %
- Pradaxa® (dabigatran etexilate) now approved in more than 100 countries for stroke prevention in atrial fibrillation
- Bristol-Myers Squibb announces charitable donation of $1 million